Formulation informed brief acceptance and commitment therapy for functional neurological disorder

ISRCTN ISRCTN48373551
DOI https://doi.org/10.1186/ISRCTN48373551
IRAS number 311583
Secondary identifying numbers IRAS 311583
Submission date
18/08/2023
Registration date
12/09/2023
Last edited
11/09/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Functional Neurological Disorder (FND) is a problem with the functioning of the nervous system and how the brain and body send and receive signals. FND has multiple causes that can vary from patient to patient. Each individual with FND can have different combinations and severity of symptoms, including problems with movement, senses and episodes of altered awareness, like seizures and blackouts. Individuals with this condition have long delays in receiving a diagnosis. This can stop individuals from developing an understanding of their condition and accessing appropriate psychological services.
Information from up-to-date research shows that a formulation, or explanation of an individual’s condition, can improve people’s quality of life and even reduce how often they experience the symptoms. Acceptance and Commitment Therapy (ACT) has been shown to also improve quality of life, mood and how symptoms affect the person. This therapy aims to help people to live well despite the difficulties they are experiencing. Currently, there is some promising evidence that ACT can help people with FND live a better life, but more research is needed. So far, no one has completed research that explores if formulation and ACT together can be helpful for people who have FND. This study is investigating if formulation and ACT-based intervention can lead to increases in psychological health, emotional processing and quality of life. While ACT does not directly aim to get rid of illness symptoms, such as seizures, the researchers want to see if symptoms may reduce anyway.

Who can participate?
Adults (18 years of age and over) with a formal diagnosis of Functional Neurological Disorder

What does the study involve?
It will require active participation for 13 weeks. During this time participants will be asked to complete some questionnaires and attend psychotherapy sessions at a local clinic. The study will involve five sessions and will require participants to answer some brief questions every other day throughout this period. After 11 weeks, participants will be contacted again a month later.

What are the possible benefits and risks of participating?
There may be no benefit to taking part in this study. However, the benefits may relate to developing a better understanding condition and developing some new coping strategies. When engaging in any psychological therapy, people may experience some psychological discomfort or distress. We are not anticipating any additional risk and no higher risk than that of standard medical care.

Where is the study run from?
Dorset Healthcare University NHS Foundation Trust (UK)

When is the study starting and how long will it run for?
November 2021 to July 2023

Who is funding the study?
University of Southampton (UK)

Who is the main contact?
1. Irma Konovalova, ik1n20@soton.ac.uk
2. Dr Warren Dunger

Contact information

Miss Irma Konovalova
Public

University of Southampton
Highfield Campus
Southampton
SO17 1BJ
United Kingdom

Phone N/A
Email I.Konovalova@soton.ac.uk

Study information

Study designSingle-case experimental design
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Community
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titleEffectiveness and acceptability of formulation and Brief-ACT intervention for functional neurological disorder
Study objectivesThe primary objectives were to establish the effect of a Formulation Informed Brief Acceptance and Commitment Therapy (F-ACT) intervention on symptom interference, measured as distress and impact on engagement in daily activities, and psychological health, emotional processing, quality of life, psychological inflexibility and understanding of functional neurological disorder (FND).

The secondary objective was to examine if the intervention benefits FND illness symptom reduction, specific to patient presentation.
Ethics approval(s)

Approved 04/11/2022, North West - Greater Manchester Central Research Ethics Committee (3rd Floor Barlow House, 4 Minshull Street, Manchester, M1 3DZ, United Kingdom; +44 (0)207 104 8057, +44 (0)207 104 8244, +44 (0)207 104 8004; gmcentral.rec@hra.nhs.uk), ref: 22/NW/0320

Health condition(s) or problem(s) studiedFunctional neurological disorder (FND)
InterventionThe intervention consisted of two parts. The first part included the development of a collaborative biopsychosocial formulation with the participant, to help them gain a better understanding of their illness, following a clinical interview. The second included three Acceptance and Commitment Therapy (ACT) sessions, based on three functional units (Triflex) that aim to increase psychological flexibility.

The study will require active participation for 13 weeks. During this time participants will be asked to complete some questionnaires and attend psychotherapy sessions at a local clinic. The study will involve five sessions and will require participants to answer some brief questions every other day throughout this period. After 11 weeks, participants will be contacted again 1 month later.
Intervention typeBehavioural
Primary outcome measureThe following questionnaires were completed at baseline, following the formulation intervention, following the ACT-based intervention and at the end of the follow-up period:
1. Quality of life (QoL) measured using the Work and Social Adjustment Scale (WSAS)
2. Emotional processing measured using the Emotional Processing Scale (EPS)
3. Psychological health measured using a 34-item Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM)
4. Psychological inflexibility measured using the Acceptance and Action Questionnaire (AAQ-II)
5. Illness perception and understanding of the condition measured using the Brief Illness Perception Questionnaire (BIPQ)
Secondary outcome measuresSymptom frequency was measured by a self-rated question “Over the last few days: (1) how often have you experienced the symptoms of your illness”. It was rated on a 10-point Likert scale ranging from 0 (no symptoms) to 10 (many severe symptoms). It was completed every 2 days throughout the length of the study.
Overall study start date08/11/2021
Completion date04/07/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit100 Years
SexBoth
Target number of participants6
Total final enrolment6
Key inclusion criteria1. Adults aged 18 years and above
2. Capable of giving informed consent
3. FND diagnosis confirmed by a neurologist
4. Sufficient English to engage in therapy
5. Not currently engaged in another psychotherapy or FND treatment
Key exclusion criteria1. Primary diagnosis of intellectual disability
2. Severe mental ill health requiring inpatient treatment or potentially affecting trial participation (e.g., suicidality, acute psychosis, active or extensive self-harm)
3. A diagnosis of a complex regional pain syndrome, dissociative identity disorder, or posttraumatic stress disorder of high severity with significant dissociation
Date of first enrolment07/11/2022
Date of final enrolment31/03/2023

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Dorset Healthcare University NHS Foundation Trust
Sentinel House
4-6 Nuffield Road
Nuffield Industrial Estate
Poole
BH17 0RB
United Kingdom

Sponsor information

University of Southampton
University/education

Highfield Campus
Southampton
SO17 1BJ
England
United Kingdom

Phone +44 (0)2380 595058
Email rgoinfo@soton.ac.uk
Website http://www.southampton.ac.uk/
ROR logo "ROR" https://ror.org/01ryk1543

Funders

Funder type

University/education

University of Southampton
Government organisation / Universities (academic only)
Alternative name(s)
University of Southampton UK
Location
United Kingdom

Results and Publications

Intention to publish date31/12/2023
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact journal and as a doctoral thesis
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date

Editorial Notes

11/09/2023: Study's existence confirmed by the HRA.